Eocene Ltd. (GLMD) News
Follow Eocene Ltd. (GLMD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Galmed rebrands as Eocene Ltd., switching ticker to EOCN
Galmed Pharmaceuticals announced a corporate rebranding to Eocene Ltd., including a change in its ticker symbol to reflect the new platform.
GEOPOLITICS | Sep 09, 2026, 11:30 AM UTC
L
Galmed Pharmaceuticals switches ticker to EOCN
Galmed Pharmaceuticals is changing its ticker symbol to EOCN.
EQUITY | Sep 09, 2026, 11:30 AM UTC
L
Galmed Pharmaceuticals Ltd reports results for the quarter ended June 30 - Earnings Summary
FORECAST CHANGESRECOMMENDATIONSThis summary was machine generated from LSEG data September 4 at 01:15 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, conta
EARNINGS | Sep 04, 2026, 01:16 AM UTC
M
Galmed reports first-in-human proof-of-concept results for Colospan technology
Galmed announces successful first-in-human proof-of-concept clinical study results for Colospan's novel intraoperative tissue assessment technology.
EQUITY | Aug 19, 2026, 11:01 AM UTC
M
Galmed announces first-in-human proof-of-concept study results for Colospan technology
Galmed says Colospan's novel intraoperative tissue assessment technology produced successful first-in-human proof-of-concept clinical study results.
EQUITY | Aug 19, 2026, 11:00 AM UTC
L
CISS, GLMD announce reverse stock splits Wednesday
CISS plans a 1-for-40 reverse split and GLMD plans a 1-for-8 reverse split for Wednesday Aug. 19.
EQUITY | Aug 19, 2026, 09:03 AM UTC
L
CISS, NRDY and GLMD announce Aug 19 reverse stock splits
CISS will execute a 1-for-40 reverse split on Aug 19, while NRDY plans a 1-for-15 reverse split and GLMD a 1-for-8 reverse split.
REGULATION | Aug 18, 2026, 08:35 PM UTC
M
CISS, NRDY, and GLMD announce reverse stock splits Aug 19
CISS is scheduled for a 1-for-40 reverse split, NRDY for a 1-for-15 reverse split, and GLMD for a 1-for-8 reverse split on Wednesday Aug 19.
REGULATION | Aug 18, 2026, 07:09 PM UTC
H
Galmed (GLMD) reports aramchol 3–4x cell death vs enzalutamide alone
Galmed announces first results from prostate oncology studies showing aramchol delivers a 3–4 fold increase in cell death versus enzalutamide (XTANDI®) alone in prostate cancer models.
EQUITY | Aug 17, 2026, 01:15 PM UTC
M
Galmed Pharmaceuticals Terminates License Agreement
Galmed terminates license agreement
EQUITY | Jul 29, 2026, 08:53 PM UTC
L
GLMD GLMD - Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibito
GLMD GLMD - Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
EQUITY | Jul 28, 2026, 11:02 AM UTC
H
Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Crown Holdings Inc (NYSE: CCK ) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY26 adjusted EPS guidance above estimates. Cro
EARNINGS | Jul 21, 2026, 09:11 AM UTC
H
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Liminatus Pharma (NASDAQ: LIMN ) stock increased by 40.9% to $0.16 during Thursday's pre-market session. The market value of their outstanding shares is at $5.8 million. Stablecoin Development (AMEX: SDEV ) stock
EARNINGS | Jul 02, 2026, 12:05 PM UTC
L
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Curis (NASDAQ: CRIS ) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ: HUMA ) shares moved upwards by 5.45% to $0.71. The marke
EQUITY | Jul 01, 2026, 09:05 PM UTC
L
Galmed Pharmaceuticals Has Received A Notice Of Allowance For A U.S. Patent Titled "TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS"
Galmed Pharmaceuticals Has Received A Notice Of Allowance For A U.S. Patent Titled "TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS"
EQUITY | Jul 01, 2026, 07:59 PM UTC
M
Healthcare Stocks Move
Multiple healthcare stocks are moving in Tuesday's after-market session, with some rising and others falling
EQUITY | Jun 23, 2026, 09:09 PM UTC
M
GLMD Increases Cash Portion
Galmed agrees to increase cash portion of purchase price for Colospan by $800K
EQUITY | Jun 22, 2026, 11:35 AM UTC
M
GLMD Restructures Acquisition Terms
Galmed Pharmaceuticals Ltd. restructures acquisition terms for Colospan Ltd., prioritizing CG-100 European commercialization and shareholder value protection.
EQUITY | Jun 22, 2026, 11:03 AM UTC